Filana Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Filana Therapeutics, Inc. (FLNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 0 shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-05-07
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was -2.28M shares, a 1180.61% decline year-over-year.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 1.70M shares, a 3081.47% increase year-over-year.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 1.36M shares, a 778.76% increase year-over-year.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.74M shares, a 314.40% increase from fiscal 2024.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 418.85K shares, a 737.72% increase from fiscal 2023.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 50.00K shares, a 44.34% increase from fiscal 2022.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 34.64K shares, a 185.35% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | -2.28M shares derived: sum of 2 quarters · filed 2026-05-07 | -582.77K shares derived: sum of 3 quarters · filed 2026-05-07 | 776.67K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | -2.28M shares derived: 10-K 12 month − 3 quarters · filed 2026-03-12 | -582.77K shares derived: sum of 2 quarters · filed 2026-03-12 | 776.67K shares derived: sum of 3 quarters · filed 2026-03-12 | 1.74M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 1.70M shares 10-Q · filed 2025-11-12 | 3.06M shares derived: sum of 2 quarters · filed 2025-11-12 | 4.01M shares derived: sum of 3 quarters · filed 2025-11-12 | 4.23M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 1.36M shares 10-Q · filed 2025-08-14 | 2.32M shares derived: sum of 2 quarters · filed 2025-08-14 | 2.53M shares derived: sum of 3 quarters · filed 2025-08-14 | 2.58M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 959.05K shares 10-Q · filed 2025-05-08 | 1.17M shares derived: sum of 2 quarters · filed 2025-05-08 | 1.22M shares derived: sum of 3 quarters · filed 2025-05-08 | 1.38M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 210.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 264.15K shares derived: sum of 2 quarters · filed 2025-03-03 | 418.85K shares derived: sum of 3 quarters · filed 2025-03-03 | 418.85K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 53.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 208.00K shares derived: sum of 2 quarters · filed 2024-11-07 | 208.00K shares 10-Q · filed 2024-11-07 | 250.86K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 154.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 154.70K shares 10-Q · filed 2024-08-08 | 197.56K shares derived: sum of 3 quarters · filed 2024-08-08 | |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-10 | 42.86K shares derived: sum of 2 quarters · filed 2024-05-10 | ||
| 2023-12-31 | 42.86K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 50.00K shares 10-K · filed 2024-02-28 | ||
| 2023-09-30 | 7.14K shares 10-Q · filed 2023-11-07 | |||
| 2022-12-31 | 34.64K shares 10-K · filed 2023-02-28 | |||
| 2021-12-31 | 12.14K shares 10-K · filed 2022-03-01 | |||
| 2020-12-31 | 382.36K shares 10-K · filed 2021-03-23 | |||
| 2019-12-31 | 179.01K shares 10-K · filed 2020-03-26 | |||
| 2018-12-31 | 314.68K shares 10-K · filed 2019-03-29 | |||
| 2017-12-31 | 479.50K shares 10-K · filed 2018-02-06 | |||
| 2016-12-31 | 1.83M shares 10-K · filed 2017-03-07 | |||
| 2015-12-31 | 38.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | 46.77K shares derived: sum of 2 quarters · filed 2016-03-03 | 1.44M shares derived: sum of 3 quarters · filed 2016-03-03 | 1.61M shares 10-K · filed 2016-03-03 |
| 2015-09-30 | 8.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | 1.40M shares derived: sum of 2 quarters · filed 2015-11-09 | 1.57M shares 10-Q · filed 2015-11-09 | |
| 2015-06-30 | 1.39M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-23 | 1.56M shares 10-Q · filed 2015-07-23 | ||
| 2015-03-31 | 167.00K shares 10-Q · filed 2015-05-08 | |||
| 2014-12-31 | 499.96K shares 10-K · filed 2015-02-18 | |||
| 2013-12-31 | 968.22K shares 10-K · filed 2014-02-05 | |||
| 2012-12-31 | 1.71M shares 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |